- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01116557
Efficacy, Safety and Efficiency Study of CARTO® 3 System Guided THERMOCOOL® Catheter Ablation Versus Fluoroscopy Guided Ablation With the Pulmonary Vein Ablation Catheter® (PVAC®) (CLARITY-AF)
CARTO® 3 System-guided RF Ablation Using the THERMOCOOL® Catheter Versus Fluoroscopy-guided RF Ablation Using the Pulmonary Vein Ablation Catheter® (PVAC®) in Subjects With Paroxysmal Atrial Fibrillation: A Prospective, Multi-center, Randomized (2:1), Controlled, Two-arm, Unblinded Clinical Study
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This study is a prospective, multi-center, randomized (2:1), controlled, two-arm, unblinded, clinical study, which will evaluate the efficacy, safety, and efficiency of CARTO® 3 System-guided RF ablation (using the THERMOCOOL® Catheter and LASSO® Circular Mapping Catheter) compared to fluoroscopy-guided RF ablation (using the PVAC®). Patients with symptomatic PAF who meet the inclusion criteria will be considered for study participation and may be enrolled if no exclusion criteria apply.
Eligible subjects who signed the study informed consent form will be randomized into one of two treatment groups:
- THERMOCOOL® Group: RF ablation to achieve PVI using the CARTO® 3 System, THERMOCOOL® Catheter and LASSO® Circular Mapping Catheter
- PVAC® Group: RF ablation to achieve PVI using fluoroscopy and the PVAC®
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Antwerpen, Belgia, 2020
- A.Z. Middelheim
-
Brugge, Belgia, 8000
- A.Z. St Jan AV
-
-
-
-
-
Värde, Dania, 6800
- Heart Center Varde
-
-
-
-
-
Eindhoven, Holandia, 5623 EJ
- Catharina Ziekenhuis
-
Zwolle, Holandia, 8011
- Isala Klinieken
-
-
-
-
-
Ontario, Kanada, L3Y 2P9
- Southlake Regional Health Centre
-
-
Ontario
-
Newmarket, Ontario, Kanada, L3Y2P9
- Southlake Regional Health Centre
-
-
-
-
-
Köln, Niemcy, 51149
- Krankenhaus Porz Cologne
-
-
-
-
Essex
-
Basildon, Essex, Zjednoczone Królestwo, SS16 5NL
- Essex Cardiothoracic Centre
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patients with PAF who have had two (2) symptomatic PAF episodes in the six (6) months prior to randomization, and who are selected for catheter ablation for the treatment of their AF. Additionally patients with recurrent AF with episodes up to 30 days with sinus rhythm maintained for more than one week following cardioversion and who require PVI only for the treatment of their AF (supported by the consensus statement2). At least one AF episode should be documented either on ECG, TTM, HM or telemetry strip.
- Failure of at least one AAD for PAF [class I or III] as evidenced by recurrent symptomatic PAF, or intolerable side effects due to the AAD.
- Signed Patient Informed Consent Form.
- Age 18 years or older.
- Able and willing to comply with all pre- and follow-up testing and requirements.
Exclusion Criteria:
- Longstanding persistent atrial fibrillation
- Patients with a history of any atrial flutter requiring ablation in the right atrium during the study procedure
- Patients in whom sinus rhythm was maintained for less than 1 week after electrical cardioversion
- Previous ablation for AF
- LA size > 55 mm
- LVEF < 40% (ejection fraction)
- AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
- CABG procedure within the last six (6) months
- Awaiting cardiac transplantation or other cardiac surgery
- Documented left atrial thrombus on imaging (eg, TEE)
- Diagnosed atrial myxoma
- Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable) or breastfeeding
- Acute illness or active systemic infection or sepsis
- Unstable angina
- Uncontrolled heart failure
- Myocardial infarction within the previous two (2) months
- History of blood clotting or bleeding abnormalities
- Contraindication to anticoagulation therapy (ie. heparin or warfarin)
- Life expectancy less than 12 months
- Enrollment in any other study evaluating another device or drug
- Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przypisanie czynnikowe
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Inny: THERMOCOOL® group
Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
|
Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
Inne nazwy:
Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
Inne nazwy:
|
Aktywny komparator: PVAC® group
Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®
|
Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
Inne nazwy:
Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Freedom from documented AF/AT recurrences without new AADs
Ramy czasowe: 1 year follow-up post-ablation
|
Subjects will be considered a success for the primary efficacy endpoint if the subject is free from documented recurrences of AF or AT lasting more than 30s as measured with Transtelephonic Monitoring and Standard of Care arrhythmia monitoring during a 3-12 month follow-up period post-ablation.
|
1 year follow-up post-ablation
|
Incidence of PV Stenosis (number of PVs with a reduction in diameter ≥ 50% at 6 months compared to baseline per CT or MRI)
Ramy czasowe: at 6 months post-ablation
|
at 6 months post-ablation
|
|
Total procedure time
Ramy czasowe: at the time of the initial ablation procedure
|
at the time of the initial ablation procedure
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Acute procedural success
Ramy czasowe: at the time of the initial ablation procedure
|
Measured by the number (%) of subjects with confirmed entrance block at the end of the ablation procedure
|
at the time of the initial ablation procedure
|
Repeat ablation procedures for AF/AT recurrences
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
Measured by % of subjects undergoing repeat ablation procedures for Recurring AF/AT
|
through 3-12 month follow-up period post-ablation
|
Freedom from documented AF/AT recurrences without AAD(s)
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
Measured by % achieving freedom from documented AF/AT recurrences
|
through 3-12 month follow-up period post-ablation
|
Freedom from documented AF/AT recurrences with AAD(s)
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
Measured by % achieving freedom from documented AF/AT recurrences
|
through 3-12 month follow-up period post-ablation
|
Freedom from documented AF/AT recurrences after more than one ablation procedure
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
Measured by % achieving freedom from documented AF/AT recurrences
|
through 3-12 month follow-up period post-ablation
|
Freedom from documented AF recurrences without AADs
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
Measured by % achieving freedom from documented AF/AT recurrences
|
through 3-12 month follow-up period post-ablation
|
Freedom from documented AF recurrences with AAD(s)
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
Measured by % achieving freedom from documented AF/AT recurrences
|
through 3-12 month follow-up period post-ablation
|
Freedom from documented symptomatic AF/AT recurrences without new AAD(s)
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
Measured by % achieving freedom from documented symptomatic AF/AT recurrences
|
through 3-12 month follow-up period post-ablation
|
Freedom from documented symptomatic AF/AT recurrences with AAD(s)
Ramy czasowe: through 3-12 month follow-up period post-ablation
|
through 3-12 month follow-up period post-ablation
|
|
Incidence of any procedure-related and/or device-related adverse events occurring during the study
Ramy czasowe: through 1 year follow-up
|
through 1 year follow-up
|
|
Incidence of any catheter-related adverse events
Ramy czasowe: during 7 days follow-up post-ablation
|
during 7 days follow-up post-ablation
|
|
Total Fluoroscopy exposure time
Ramy czasowe: at the time of the ablation procedure
|
Measured by fluoroscopy and cine-fluoroscopy time throughout procedure
|
at the time of the ablation procedure
|
Total Fluoroscopy Dose-Area Product/Source Intensifier Distance
Ramy czasowe: at the time of the ablation procedure
|
at the time of the ablation procedure
|
|
Incidence of any phrenic nerve paralysis
Ramy czasowe: through 1 year follow-up post-ablation
|
through 1 year follow-up post-ablation
|
|
Incidence of any symptomatic Transient Ischemic Attack (TIA) or Cerebrovascular Accident (CVA)
Ramy czasowe: through 1 year follow-up post-ablation
|
through 1 year follow-up post-ablation
|
|
Number of mapping and ablation catheters used per subject
Ramy czasowe: through 1 year follow-up post-ablation
|
through 1 year follow-up post-ablation
|
|
Quality of Life (SF-36®) and Atrial Fibrillation Symptom Frequency and Severity Checklist assessment
Ramy czasowe: Baseline, 3, 6 and 12 months
|
Baseline, 3, 6 and 12 months
|
|
Total procedure hospital visit and ablation procedure costs
Ramy czasowe: during hospitalization stay for study treatment
|
during hospitalization stay for study treatment
|
|
Total number of initial or prolonged hospitalizations and unscheduled arrhythmia-related health care provider visits (including emergency department visits)
Ramy czasowe: through 1 year follow-up post-ablation
|
through 1 year follow-up post-ablation
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Mattias Duytschaever, MD, A.Z. St Jan AV
- Główny śledczy: Yves De Greef, MD, A.Z. Middelheim
- Główny śledczy: Stuart Harris, MD, Essex Cardiothoracic Centre
- Główny śledczy: Peter Steen Hansen, MD, Heart Center Varde
- Główny śledczy: Pepijn Van Der Voort, MD, Catharina Ziekenhuis
- Główny śledczy: Thomas Deneke, MD, Krankenhaus Porz Cologne
- Główny śledczy: Arif Elvan, MD, Isala
- Główny śledczy: Yaariv Khaykin, MD, Southlake Regional Health Centre
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- BWI130
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Radiofrequency Ablation procedure
-
Abbott Medical DevicesZakończonyUtrwalone migotanie przedsionkówStany Zjednoczone, Australia
-
Pier LambiaseUniversity Hospital Southampton NHS Foundation Trust; The Royal Bournemouth...ZakończonyMigotanie przedsionkówZjednoczone Królestwo
-
Yonsei UniversityZakończony
-
Universidad de GranadaRekrutacyjny
-
Newmarket Electrophysiology Research Group IncMedtronicZakończony
-
Ryazan State Medical UniversityAktywny, nie rekrutującyChoroby naczyniowe | Żylaki kończyn dolnych | Obrzęk nóg | VarixFederacja Rosyjska
-
Abimbola FamuyideHologic, Inc.ZakończonyKrwotok miesiączkowyStany Zjednoczone